targeted, non-myeloablative Busulphan dosing, with measurement of area-under-the-curve (AUC) and dose adjustment accordingly has been considered an attractive option for conditions where full myeloablative conditioning is not required or potentially harmful. Here we describe the use of targeted, non-myeloablative Busulphan dosing, alongside Fludarabine and serotherapy, including alemtuzumab in the majority of these patients, in a cohort of patients with HLH and disorders predisposing to HLH in a single centre.
Children who had undergone HSCT between 2011 and 2015 with reduced intensity Busulphan and Fludarabine conditioning for a clinical diagnosis of HLH or a primary immunodeficiency predisposing to HLH were identified from immunology and oncology departmental records. Local hospital human research ethics committee (HREC) approval was obtained for collection of data from medical records. Data collection included patient demographics, conditioning regimen, donor source, stem cell dose and Busulphan AUC. Outcome was determined by survival at 30 days post-transplant, 1 year and at most recent followup. Donor chimerism, both whole blood and lineagespecific as indicated, was evaluated at day 30, 1 year and most recent follow-up. Children were determined to have active HLH preceding HSCT if they met clinical criteria for HLH and required treatment. Busulphan AUC measurement was performed after the first single-daily dose, as per protocol. Pharmacokinetic (PK) results were used to dose adjust from the second dose, with a cap applied at a maximum 20% dose increase.
Between 2011 and 2015, 12 patients (6 male) underwent HSCT using a reduced intensity, targeted Busulphan-based conditioning regimen for HLH (Table 1) . Mean age at HSCT was 5.2 years (range 0.4-12.3). Two children who received cord blood transplants received anti-thymocyte globulin as serotherapy. The remaining 10 children received alemtuzumab, which is likely to have contributed to immunodepletion prior to HSCT. All children received up to 3 mg/kg depending on clinical status, and all doses were administered distal or intermediate to infusion. Three patients required additional doses of alemetuzumab prior to HSCT, none of which were administered after day (d)-10. All received cyclosporine for GvHD prophylaxis, 10 had additional mycophenolate mofetil, one received additional methylprednisolone and one methotrexate.
Mean stem cell dose was 4.1 × 10 6 /kg (range 0.12-11.4). Ten children required increased dosing of Busulphan for subsequent doses based on first day PK data. Median time to neutrophil engraftment was 22 days (range 10-28 days). Five children developed acute grade I-II skin or gut Graftversus-host disease (GvHD). No patients developed grade III-IV GvHD.
A total of 11/12 patients survived to 30 days, with one death at day +26. There was a further death at day +41. Both children who died received an unrelated cord blood transplant, and failed to achieve neutrophil engraftment. One child had X-linked lymphoproliferative syndrome type 1 (XLP1) due to an SHD21A mutation. He presented with pancytopenia, protracted diarrhoea, growth failure and persistent fevers, with radiological suspicion of a fungal lung nodule. He had catastrophic gastrointestinal bleeding prior to transplant, and was treated with alemtuzumab as a bridge to HSCT. He succumbed to multi-organ failure with graft failure on d +26. The other child had compound heterozygous UNC13D mutations and presented with HLH with central nervous system (CNS) involvement at 6 months of age. She contracted Respiratory Syncytial Virus and Adenovirus prior to HSCT, and had reactivation of both viruses post-HSCT. She succumbed to respiratory failure with failure to engraft at day +41. Ten (83%) children have survived longer than 1 year post-HSCT. Mean follow-up is 3.1 years (range 1.04-4.93 years). Chimerism is >95% donor in 9/10 surviving children at 1 year post HSCT and most recent follow-up. To date, no patients have required donor lymphocyte infusions (DLI) or stem cell boost, and no patients had clinical reactivation of HLH posttransplant.
The management of patients with HLH primarily consists of immune suppression, identification and treatment of any identifiable trigger, such as a viral infection, and for children with a molecular diagnosis predisposing to HLH, or presumed primary HLH, progression to haematopoietic stem cell transplant [5] . Although the rate of clinical response to current HLH treatment protocols is high, HSCT is the only treatment that provides a potential cure in patients with a genetic aetiology for their disease [5] . Traditional myeloblative conditioning regimens, used initially for patients with malignant disease, have been associated with poor outcomes, particularly in patients with HLH, including high rates of transplant-related morbidity and mortality [4, 5] . As an alternative, reduced intensity conditioning regimens, including Fludarabine, Melphalan, and Alemtuzumab, have been used more recently in HLH transplantation, and found to have lower rates of short-and long-term transplant-related complications, including GvHD and veno-occlusive disease, and lower mortality [4, 5] . However, mixed donor chimerism occurs in 30-75% of patients receiving RIC, with the associated risk of graft failure and HLH recurrence [9] . A recent multicentre retrospective study suggests that donor chimerism >20-30% is considered protective against late HLH reactivation, although lower levels of chimerism do not necessarily lead to recurrence [9] . Achieving a balance between reducing short-and long-term complications while providing sufficient long-term donor chimerism to prevent disease reactivation is ultimately the goal of HSCT for patients with HLH. Styczynksi et al. [10] reported the results of a pilot study of a Busulphan, Fludarabine, and Alemtuzumab reduced intensity conditioning regimen for HSCT in 12 children with malignant and non-malignant diseases, with an overall survival of 91.7 ± 8% at 3 years and ≥80% donor chimerism in ≥90% of patients. This conditioning was well tolerated, with low rates of toxicity and GvHD. No patients with HLH were included in this small pilot study. Similarly, Law et al. [11] reported the use of a Busulphan, Fludarabine, and Alemtuzumab conditioning regimen in 35 paediatric patients with malignant and non-malignant disease, including two patients with HLH. Overall survival was 78% ± 7.5% at a median of 35 months post-HSCT, with a median whole-blood donor chimerism of 87% at 1-year follow-up, and low rates of acute and chronic GvHD [11] .
Here we present data that demonstrate targeted Busulphan dosing, alongside Fludarabine and serotherapy is a viable conditioning regimen in a cohort of paediatric patients with a HLH diagnosis or mutations in genes predisposing to HLH. This regimen resulted in good donor chimerism, without substantial morbidity, and could be considered an alternative to current RIC regimens that are associated with higher rates of mixed donor chimerism. However, larger studies using this conditioning regimen would be necessary to support this finding.
